Prism Medico & Pharmacy Fair Value
Prism Medico & Pharmacy (PRISMMEDI) average fair value is ₹15.32 across 5 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, vs a current market price of ₹30.9 (-50.43%), fair value range ₹4.35–₹31.2. Examine Prism Medico & Pharmacy quarterly earnings for recent quarterly revenue, profit and EPS trends.
Fair Value Analysis Export
PRISMMEDI Fair Value vs Current Price — Valuation Summary
PRISMMEDI average fair value, fair value range, price gap and valuation status across 5 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number. See PRISMMEDI price to book ratio to compare market price against book value per share.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
PRISMMEDI Fair Value Analysis — Data Sources & Coverage
Prism Medico & Pharmacy financial data sources, valuation methods applied and sector benchmarks used — 2019 financial year. For live price and a broader fundamental view, visit Prism Medico & Pharmacy stock price NSE.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
Data Currency: Financial data is 7 years old (2019).
PRISMMEDI vs Financial Services Sector Peers — P/E, P/B & Market Cap
Prism Medico & Pharmacy P/E ratio, P/B ratio and market capitalisation vs Financial Services sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Trishakti Electronics | TRISHAKT | 34.09 | 5.69 | ₹252 |
| Indo Credit Capital | INDOCRED | 124.78 | 1.41 | ₹8 |
| Shri Niwas Leasing and F… | SHRINIWAS | -0.04 | -0.04 | ₹4 |
| Ajcon Global Services | AJCON | - | 1.55 | ₹39 |
| Virat Leasing | VLL | -185.36 | 8.28 | ₹135 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.